(Health Korea News / Lee Si-woo) Dong-A ST (CEO and President Jeong Jae-hoon) announced on the 8th that it participated in the ‘Swiss Basel Investment Authority KPBMA Customized Networking Event’ held in Basel, Switzerland on the 7th and showcased Dong-A ST’s R&D capabilities and competitiveness.
This event is part of the ‘Swiss Basel Investment Authority KPBMA customized program’ operated by the Korea Pharmaceutical and Biotechnology Association and the Basel Investment Authority to support domestic pharmaceutical companies entering Europe. Held under the theme of ‘Measures to enhance collaboration with Korea’s promising pharmaceutical companies’, the competitiveness of the Korean pharmaceutical and bio industry and the companies’ pipelines were introduced to global big pharma and biotech companies, European academia and research institutes, etc.
At the event, Jaehong Park, CEO of Dong-A ST R&D, introduced Dong-A ST’s major clinical assets in the R&D field, including anti-cancer, inflammation, and neurology. Through networking activities, various cooperation plans were proposed, including partnerships and expansion of business opportunities with Swiss and European pharmaceutical and bio companies and research institutes. groped.
Dong-A ST is developing a Stelara biosimilar, ‘Imuldosa’, which has received a recommendation for product approval from the European CHMP; GLP-1, a Glucagon dual agonist under development as an obesity treatment, ‘DA-1726’; and MASH (Metabolic dysfunction-associated steatohepatitis). ‘DA-1241’ being developed as a treatment for steatohepatitis, ‘DA-4505’ being developed as an immunotherapy, and ‘DA-4505’ being developed as a dementia treatment. It has pipelines such as ‘DA-7503’.
Since last year, Dong-A ST has participated in the ‘Swiss Basel Investment Authority KPBMA Customized Program’ and is actively carrying out cooperation and networking activities with Swiss global pharmaceutical companies, biotech companies, promising startups, universities, and research institutes.
“It was a significant opportunity to publicize Dong-A ST’s R&D competitiveness by participating in an international event held in a global pharmaceutical and bio hub,” said Dong-A ST R&D CEO Park Jae-hong. “We will continue to promote the Korean pharmaceutical and bio industry on the global stage, including the European market.” “We will raise our status and achieve sustainable growth through differentiated research and development,” he said.
Meanwhile, Dong-A ST’s R&D CEO Park Jae-hong participated as a panelist at the ‘Korea-Sweden Cross-Border Conference’ held in Stockholm, Sweden on the 6th, and said, ‘Acceleration of research and business development between the two countries, investment and A discussion was held on the topic of ‘Fostering Strategic Partnerships’.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
